Incyte Reports Positive Results from Phase II Clinical Trial of Oral JAK1 Inhibitor
Incyte Corporation (NASDAQ: INCY) announced results from a 28-day,
placebo-controlled, dose-escalation Phase II proof-of-concept clinical
trial involving 50 patients with chronic plaque psoriasis for its
proprietary oral JAK1 inhibitor, INCB39110. The results were presented
by Robert Bissonnette, M.D., President of Innovaderm Research Inc. and
co-lead investigator, today at the European Academy of Dermatology and
Venereology (EADV) Congress in Istanbul, Turkey.
In the trial, evidence of efficacy was observed in patients treated with
INCB39110 at all doses as measured by static physician global assessment
(sPGA) and psoriasis area and severity index (PASI) as compared to
patients treated with placebo. INCB39110 was generally well-tolerated
with no evidence of myelosuppression.